CLINICAL TRIALS PROFILE FOR DYNABAC
✉ Email this page to a colleague
All Clinical Trials for DYNABAC
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02185833 ↗ | Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition | Completed | Abdi Ibrahim Ilac San. ve Tic A.S. | Phase 1 | 2014-06-01 | To assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Erythromycylamine and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation. |
NCT02185833 ↗ | Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition | Completed | Pharmaceutical Research Unit, Jordan | Phase 1 | 2014-06-01 | To assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Erythromycylamine and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation. |
NCT02185846 ↗ | Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition | Completed | Abdi Ibrahim Ilac San. ve Tic A.S. | Phase 1 | 2014-06-01 | To assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Erythromycylamine and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation. |
NCT02185846 ↗ | Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition | Completed | Pharmaceutical Research Unit, Jordan | Phase 1 | 2014-06-01 | To assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Erythromycylamine and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation. |
NCT02237768 ↗ | Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions | Completed | Abdi Ibrahim Ilac San. ve Tic A.S. | Phase 1 | 2014-12-01 | The purpose of this study is to assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Erythromycylamine and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DYNABAC
Condition Name
Clinical Trial Locations for DYNABAC
Clinical Trial Progress for DYNABAC
Clinical Trial Phase
Clinical Trial Sponsors for DYNABAC
Sponsor Name